Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells $35,395.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 500 shares of the stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $70.79, for a total value of $35,395.00. Following the sale, the vice president directly owned 73,924 shares of the company’s stock, valued at $5,233,079.96. The trade was a 0.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

• On Thursday, August 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $75.48, for a total transaction of $37,740.00.
• On Monday, July 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $81.84, for a total value of $40,920.00.

ANI Pharmaceuticals Price Performance

ANIP stock traded up $0.21 on Monday, reaching $70.40. 357,649 shares of the company’s stock were exchanged, compared to its average volume of 331,768. The stock has a fifty day moving average of $76.97 and a 200-day moving average of $78.17. ANI Pharmaceuticals, Inc. has a twelve month low of $69.58 and a twelve month high of $99.39. The firm has a market cap of $1.62 billion, a PE ratio of 15.17 and a beta of 0.45. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The company had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. During the same quarter last year, the company earned $1.80 earnings per share. ANI Pharmaceuticals’s quarterly revenue was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current fiscal year.

Institutional Trading of ANI Pharmaceuticals

A number of hedge funds have recently made changes to their positions in ANIP. California State Teachers Retirement System grew its holdings in ANI Pharmaceuticals by 7,977.4% during the 2nd quarter. California State Teachers Retirement System now owns 1,983,574 shares of the specialty pharmaceutical company’s stock valued at $164,200,000 after purchasing an additional 1,959,017 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in shares of ANI Pharmaceuticals by 19.3% in the first quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company’s stock worth $43,399,000 after acquiring an additional 91,153 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in ANI Pharmaceuticals by 8.9% in the first quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company’s stock valued at $40,843,000 after purchasing an additional 43,523 shares during the last quarter. Ranger Investment Management L.P. acquired a new stake in ANI Pharmaceuticals during the 2nd quarter valued at approximately $28,406,000. Finally, Deutsche Bank AG purchased a new stake in ANI Pharmaceuticals during the 2nd quarter worth approximately $26,775,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on ANIP shares. Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, September 9th. They issued an “outperform” rating and a $104.00 price objective on the stock. Canaccord Genuity Group cut their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research report on Monday, August 10th. Weiss Ratings lowered shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Wall Street Zen downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Finally, Guggenheim dropped their price objective on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research report on Monday, August 10th. Five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $105.57.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.

ANI’s portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.